T. Rowe Price Investment Management, Inc., a registered investment adviser, initiated a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 1,753,640 shares of the Healthcare company, valued at approximately $697.3M as of the filing date.
Alnylam Pharmaceuticals, Inc.'s stock currently trades at $331.74 with a market capitalization of $54.5B.